Article
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
Cancer science - 1 May 2011
Shukuya Takehito, Takahashi Toshiaki, Kaira Rieko, Ono Akira, Nakamura Yukiko, Tsuya Asuka, Kenmotsu Hirotsugu, Naito Tateaki, Kaira Kyoichi, Murakami Haruyasu, Endo Masahiro, Takahashi Kazuhisa, Yamamoto Nobuyuki
Abstract excerpt
The efficacy of gefitinib for patients with non-adenocarcinoma non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because only a small percentage of patients enrolled in the clinical trials to evaluate the efficacy of gefitinib for tumors harboring EGFR mutation were non-adenocarcinoma NSCLC. A pooled analysis was conducted to clarify the efficacy of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.